19.09.2018 | Nanion Technologies and Ncardia Sign Co-Marketing and Support Agreement to enhance Options for Cardiac Researchers
MUNICH, Germany and COLOGNE, Germany, September 19, 2018-- Nanion Technologies GmbH, a leading provider of instrumentation for ion channel drug discovery and screening, and the Ncardia Group, a leading developer, manufacturer, and service provider of human induced pluripotent stem cells (iPSCs) for safety and efficacy testing announced today that they have entered into a joint marketing and sales promotion agreement.